Perspective Therapeutics (NYSE:CATX) Given “Outperform” Rating at Oppenheimer

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Oppenheimer in a report released on Friday, Benzinga reports. They presently have a $22.00 price target on the stock. Oppenheimer’s price objective suggests a potential upside of 89.66% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. Bank of America began coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective on the stock. Wedbush initiated coverage on Perspective Therapeutics in a research note on Tuesday, October 1st. They issued an “outperform” rating and a $25.00 target price for the company. Royal Bank of Canada lowered their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a report on Friday, August 16th. Truist Financial initiated coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $21.43.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded down $1.65 during midday trading on Friday, reaching $11.60. The company’s stock had a trading volume of 3,896,867 shares, compared to its average volume of 678,128. The stock’s 50-day moving average is $13.82. Perspective Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. On average, research analysts expect that Perspective Therapeutics will post -0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new stake in shares of Perspective Therapeutics during the second quarter valued at about $117,000. Point72 DIFC Ltd acquired a new stake in Perspective Therapeutics during the 2nd quarter valued at approximately $118,000. SG Americas Securities LLC purchased a new stake in Perspective Therapeutics during the 3rd quarter worth approximately $246,000. The Manufacturers Life Insurance Company acquired a new position in shares of Perspective Therapeutics in the 2nd quarter valued at approximately $188,000. Finally, Iowa State Bank purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $254,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.